This event is now closed, information is displayed here for information only.

The 2017 ‘Frontiers of Oncology: Haematology’ meeting will be announced in January 2017

but you can pre-register HERE to be advised when the programme is released

 

A one day meeting held on
Friday 1st July 2016
The Royal College of Physicians, London, UK

---

Chairs

Professor Tariq Enver Director UCL Cancer Institute

Professor Adele Fielding Professor of Haematology UCL Cancer Institute

---

From 08.00	Registration & Coffee
09.00	Welcome to the event / setting the scene: the Chairmen
	SESSION 1: BMT
09.05	Introduction from session Chair: Professor Tariq Enver
09.10	Targeted radiotherapy – Radio-labelled anti-CD66 antibodies for allograft conditioning Dr Kim Orchard Senior Lecturer, University of Southampton
09.30	The influence of reduced intensity conditioning and the future of allograft conditioning regimens Professor Stephen Mackinnon Professor of Haematology, UCL Cancer Institute, London, UK
09.50	Progress towards separating GVHD from GVL Professor Ronjon Chakraverty Professor of Cellular Immunotherapy, UCL Cancer Institute, London, UK
10.10	Q&A All
10.25	Break
	SESSION 2: Lymphoma
10.55	Introduction from session Chair: Professor David Linch
11.00	Immune checkpoint therapy for lymphomas (inc. Q&A) Professor Karl Peggs Professor of Stem Cell Transplantation & Immunotherapy, UCL Cancer Institute, London, UK
11.25	Recent genetic insights into lymphoma (inc. Q&A) Professor Jude Fitzgibbon Professor of Personalised Cancer Medicine, Bart’s Cancer Institute, London, UK
11.50	State of the art therapy for rare lymphoma subtypes (inc. Q&A) Dr Kate Cwynarski Consultant Haematologist UCLH, Honorary Clinical Senior Lecturer UCL Cancer Institute, London, UK
12.15	Summary
12.20	Lunch
	SESSION 3: ALL / AML
13.10	Introduction from session Chair: Adele Fielding
13.15	T ALL – A summary of the genetic landscape and its impact on therapeutic outcome Dr Marc Mansour Professorial Research Fellow, UCL Cancer Institute, London, UK
13.35	Novel approaches to treating B-ALL Professor Adele Fielding Professor of Haematology, UCL Cancer Institute, London, UK
13.55	Challenges associated with the molecular heterogeneity in AML Professor Rosemary Gale Professor of Haematology, UCL Cancer Institute, London, UK
14.15	Q&A
14.30	Break
	SESSION 4: Myeloma
15.00	Introduction from session Chair: Professor Kwee Yong
15.05	Bromodomain inhibitors explained and their potential utility in the therapy of multiple myeloma Professor Anastasios Karadimitris Professor of Haematology, Imperial College London, UK
15.30	Early clinical development of new treatments in myeloma Dr Rakesh Popat Consultant Haematologist at UCLH, Honorary Clinical Senior Lecturer at the UCL Cancer Institute, London, UK
15.55	A redefinition of myeloma Dr Jenny Bird Consultant Haematologist, University Hospitals Bristol, UK
16.30	Summary & Close

This meeting is organised by:

and endorsed and supported by:

---

The Frontiers of Oncology 2019 meetings are supported by the Pharmaceutical Industry.
As support agreements are reached, disclosure of the supporters is listed here.